Saturday 2 June 2012

Boots Antifungal Cream





1. Name Of The Medicinal Product



Asda Thrush Relief Cream



Lloydspharmacy Antifungal Skin Cream



Lloydspharmacy Thrush Femme Cream



Clotrimazole 1% cream BP



Boots Antifungal Cream



Tesco Antifungal Cream



Morrisons Thrush Relief Cream



Teva Thrush Relief 1% w/w Cream


2. Qualitative And Quantitative Composition



Clotrimazole B.P. 1% w/w



3. Pharmaceutical Form



Cream



4. Clinical Particulars



4.1 Therapeutic Indications



For the treatment of skin infections due to dermatophytes (e.g. trycophyton species), yeasts (e.g. candida species), moulds and other fungi. These include ringworm (tinea) infections, paronychia, pityriasis versicolor, erythrasma and intertrigo, as well as fungal nappy rash, candidal vulvitis and candidal balanitis.



4.2 Posology And Method Of Administration



Dosage:



Adult, children and elderly:



Apply to the affected area two or three times daily



Dermatophyte infections: treat for at least one month



Candida infections: treat for at least two weeks



Route of administration:



Directly applied to the affected area.



A physician should be consulted if symptoms do not improve within 7 days.



4.3 Contraindications



Known hypersensitivity to any of the components



4.4 Special Warnings And Precautions For Use



The cream contains cetyl alcohol and stearyl alcohol, which may cause local skin reaction (e.g. contact dermatitis).



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

Clotrimazole Cream may cause damage to latex contraceptives. Consequently patient should be advised to use alternative precautions for at least five days after using this product.


4.6 Pregnancy And Lactation



Pregnancy



Data on a large number of exposed pregnancies indicate no adverse effects of Clotrimazole on pregnancy or on the health of the foetus/newborn child. To date, no other relevant epidemiological data are available.



Clotrimazole can be used during pregnancy, but only under the supervision of a physician or midwife.



Breast-feeding



It is unknown whether clotrimazole is excreted in breast milk, so it should be given with caution to lactating mothers.



4.7 Effects On Ability To Drive And Use Machines



None known



4.8 Undesirable Effects



As the listed undesirable effects are based on spontaneous reports, assigning accurate frequency of occurrence for each is not possible.



Immune system disorders: allergic reaction (syncope, hypotension, dyspnoea, urticaria)



Skin and subcutaneous tissue disorders: blisters, discomfort/pain, oedema, irritation, peeling/exfoliation, pruritus, rash, stinging/burning



4.9 Overdose

In the event of accidental oral ingestion, gastric lavage is rarely required and should be considered only if a life-threatening amount of clotrimazole has been ingested within the preceding hour or if clinical symptoms of overdose become apparent (e.g. dizziness, nausea or vomiting). It should be carried out only if the airway can be protected adequately.


5. Pharmacological Properties



5.1 Pharmacodynamic Properties



ATC code: D01A C01



Clotrimazole is an imidazole derivative with a broad spectrum of antimycotic activity. It also exhibits activity against Trichomonas, staphylococci, streptococci and Bacteroides. It has no effect on lactobacilli.



Mechanism of action



Clotrimazole acts against fungi by inhibiting ergosterol synthesis. Inhibition of ergosterol synthesis leads to structural and functional impairment of the cytoplasmic membrane.



Pharmacodynamic effects



Clotrimazole has a broad antimycotic spectrum of action in vitro and in vivo, which includes dermatophytes, yeasts, moulds, etc.



The mode of action of clotrimazole is fungistatic or fungicidal depending on the concentration of clotrimazole at the site of infection. In-vitro activity is limited to proliferating fungal elements; fungal spores are only slightly sensitive.



Primarily resistant variants of sensitive fungal species are very rare; the development of secondary resistance by sensitive fungi has so far only been observed in very isolated cases under therapeutic conditions.



5.2 Pharmacokinetic Properties



Pharmacokinetic investigations after dermal application have shown that clotrimazole is minimally absorbed from the intact or inflamed skin into the human blood circulation. The resulting peak serum concentrations of clotrimazole were below the detection limit of 0.001 mcg/ml, suggesting that clotrimazole applied topically is unlikely to lead to measurable systemic effects or side effects.



5.3 Preclinical Safety Data



There are no preclinical data of reference to the prescriber which are additional to the information included in other sections of the SPC.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Sorbitan stearate



Polysorbate 60



Cetyl Esters Wax



Stearyl Alcohol



Cetyl Alcohol



2-Octyldodecanol



Benzyl Alcohol



Purified Water



6.2 Incompatibilities



None known



6.3 Shelf Life



36 months



6.4 Special Precautions For Storage



None



6.5 Nature And Contents Of Container



Aluminium tube with polypropylene screw-on cap containing 20/30/50g of cream.



6.6 Special Precautions For Disposal And Other Handling



None



7. Marketing Authorisation Holder



Teva UK Limited



Brampton Road



Hampden Park



Eastbourne



East Sussex



BN22 9AG



8. Marketing Authorisation Number(S)



PL 00289/1490



9. Date Of First Authorisation/Renewal Of The Authorisation



27 January 1998 / 08 April 2003



10. Date Of Revision Of The Text



06/06/2011




No comments:

Post a Comment